ALPHAGAN

This brand name is authorized in Austria, Australia, Brazil, Canada, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug ALPHAGAN contains one active pharmaceutical ingredient (API):

1 Brimonidine UNII 4S9CL2DY2H - BRIMONIDINE TARTRATE

Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts. Read about Brimonidine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ALPHAGAN Eye drops, solution	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
ALPHAGAN P Ophthalmic solution / drops	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01EA05	Brimonidine	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EA Sympathomimetics in glaucoma therapy
Discover more medicines within S01EA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 5298W, 5534G, 5563T, 8351M
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501000301175318, 501000302171316, 501000401171314, 501006401171313, 501016060012403
Country: CA	Health Products and Food Branch	Identifier(s): 02236876, 02248151
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 25.856-08-04
Country: EE	Ravimiamet	Identifier(s): 1238880, 1609477, 1755806
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 62010
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 174433, 174664
Country: FR	Base de données publique des médicaments	Identifier(s): 68451230
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 138272, 13845, 140550, 161371, 374168
Country: HK	Department of Health Drug Office	Identifier(s): 50368
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-063917030
Country: IE	Health Products Regulatory Authority	Identifier(s): 11298, 11301, 11306, 13033
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4785
Country: IT	Agenzia del Farmaco	Identifier(s): 033490020, 044819011, 045282011, 045633017, 045769015
Country: MT	Medicines Authority	Identifier(s): MA1304/00201
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 147M98
Country: NL	Z-Index G-Standaard	Identifier(s): 14181150
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 50237
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11926, 7798
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100100520
Country: SG	Health Sciences Authority	Identifier(s): 09788P, 12336P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699490561041
Country: US	FDA, National Drug Code	Identifier(s): 0023-9177, 0023-9321
Country: ZA	Health Products Regulatory Authority	Identifier(s): A39/15.4/0202